Different Treatment Modalities of Colo-Rectal Cancer (Retrospective Study) | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 6, Volume 81, Issue 5, October 2020, Page 1953-1957 PDF (354.95 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2020.123478 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Abbas Mahmoud Sarhan1; Mohammed Abdelgawad Soliman1; Eman Ali El-Sebai1; Mahmoud Mohammed Ahmed El-Demery  2
| ||||
| 1Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Sharkia, Egypt. | ||||
| 2Department of Clinical Oncology & Nuclear Medicine, Ahmed Maher Teaching Hospital, Cairo, Egypt | ||||
| Abstract | ||||
| Background: Colorectal Cancer (CRC) is the most common type affecting the gastrointestinal tract accounting for about 13% of all malignancy diagnosed each year. Although Surgery stays the most effective treatment in managing colorectal carcinoma, there is a rapid increase in the use of preoperative radiotherapy and chemotherapy. Objective: So, the present study was conducted to identify the different therapeutic modalities used in the treatment. Patients and Methods: This study was a retrospective study that included CRC patients treated at the Clinical Oncology Department, Zagazig University Hospital during the period from 2012 to 2017. Medical records of 385 patients, who were referred to the Clinical Oncology Department after being diagnosed with CRC were obtained and used to collect data about different treatments and then analyzed. Results: Chemotherapy regimen FOLFOX was received in (45.5%) of cases and partial response in 41 % of cases was observed. Patients received at least one line of chemotherapy with either adjuvant or palliative intent. Rectal cancer patients who received neoadjuvant concurrent chemo& radiotherapy showed a partial response in 45.5 % of cases. Xeloda was the most common chemotherapy received in most cases who received either adjuvant or neoadjuvant CCRT. Recurrence occurred in (81%) of cases. Conclusion: Chemotherapy regimen FOLFOX was received in most cases. Patients received at least one line of chemotherapy with either adjuvant or palliative intent, FOLFOX was the most chosen protocol. Xeloda was the most common chemotherapy received in most cases | ||||
| Keywords | ||||
| treatment modalities; Colorectal Cancer; Retrospective | ||||
|
Statistics Article View: 169 PDF Download: 407 |
||||
